A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer

Our aim was to systematically evaluate the benefits of degarelix as antagonist versus agonists of gonadotropin-releasing hormones (GnRH) for the treatment of advanced prostate cancer (PC). This comparison was performed either in terms of biochemical or oncological or safety profiles. To this end we,...

Descripción completa

Detalles Bibliográficos
Autores principales: Sciarra, Alessandro, Fasulo, Andrea, Ciardi, Antonio, Petrangeli, Elisa, Gentilucci, Alessandro, Maggi, Martina, Innocenzi, Michele, Pierella, Federico, Gentile, Vincenzo, Salciccia, Stefano, Cattarino, Susanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
7300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058791/
https://www.ncbi.nlm.nih.gov/pubmed/27399062
http://dx.doi.org/10.1097/MD.0000000000003845

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058791/
https://www.ncbi.nlm.nih.gov/pubmed/27399062
http://dx.doi.org/10.1097/MD.0000000000003845

Ejemplares similares